NASDAQ:GOSS

Gossamer Bio - GOSS Stock Forecast, Price & News

$2.78

-0.14 (-4.79%)

(As of 02/3/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.76
▼
$2.98
50-Day Range: $1.74
▼
$9.29
52-Week Range: $1.57
▼
$15.19

Volume: 4.03 million shs
Average Volume: 3.53 million shs
Market Capitalization: $262.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.25

Institutional Ownership

Gossamer Bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 268.7% Upside
$10.25 Price Target
Short Interest: Bearish
38.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.75) to ($2.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

393rd out of 1,028 stocks

Pharmaceutical Preparations Industry

188th out of 501 stocks

4.3

Analyst's Opinion

Consensus Rating
Gossamer Bio has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 7 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $10.25, Gossamer Bio has a forecasted upside of 268.7% from its current price of $2.78.
Amount of Analyst Coverage
Gossamer Bio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
38.34% of the float of Gossamer Bio has been sold short.
Short Interest Ratio / Days to Cover
Gossamer Bio has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Gossamer Bio has recently increased by 1.04%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Gossamer Bio does not currently pay a dividend.
Dividend Growth
Gossamer Bio does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Gossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Gossamer Bio is -0.67.

0.0

News and Social Media Coverage

Search Interest
Only 10 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gossamer Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.30% of the stock of Gossamer Bio is held by insiders.
Percentage Held by Institutions
90.18% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Gossamer Bio are expected to grow in the coming year, from ($2.75) to ($2.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gossamer Bio is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gossamer Bio is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gossamer Bio has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

January 4, 2023 | finance.yahoo.com

Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?

January 4, 2023 | finance.yahoo.com

Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

February 5, 2023 | Wall Street Watch Dogs (Ad)

A gold storm is coming…

“We are in the early stages of a mania – the calm before the storm.”...

January 3, 2023 | msn.com

Looking Into Gossamer Bio's Recent Short Interest

December 27, 2022 | msn.com

180 Life Sciences, KalVista top healthcare gainers; Edesa, Nutex among losers

December 26, 2022 | finance.yahoo.com

Bullish insiders at Gossamer Bio, Inc. (NASDAQ:GOSS) loaded up on US$1.2m of stock earlier this year

December 8, 2022 | seekingalpha.com

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

December 7, 2022 | marketwatch.com

Gossamer Bio: Seralutinib Meets Primary Endpoint in Phase 2 Trial in PAH

February 5, 2023 | Wall Street Watch Dogs (Ad)

A gold storm is coming…

“We are in the early stages of a mania – the calm before the storm.”...

December 7, 2022 | seekingalpha.com

Gossamer Bio downgraded to Equal Weight at Barclays after PAH readout

December 7, 2022 | msn.com

Barclays Downgrades Gossamer Bio: Here's What You Need To Know

December 7, 2022 | markets.businessinsider.com

What 9 Analyst Ratings Have To Say About Gossamer Bio

December 7, 2022 | msn.com

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

December 7, 2022 | proactiveinvestors.com

Gossamer Bio tumbles as hypertension drug underperforms rival product in Phase 2 trial

December 6, 2022 | seekingalpha.com

Gossamer sheds 63% even as PAH candidate reaches main goal in Phase 2 trial

December 6, 2022 | seekingalpha.com

Gossamer Bio selloff is an overreaction - Piper Sandler

December 6, 2022 | finance.yahoo.com

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

November 25, 2022 | finance.yahoo.com

Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial

November 17, 2022 | markets.businessinsider.com

4 Analysts Have This to Say About Gossamer Bio

November 8, 2022 | msn.com

What Makes Gossamer Bio (GOSS) a New Buy Stock

November 3, 2022 | finance.yahoo.com

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

October 24, 2022 | finance.yahoo.com

Goldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential

October 20, 2022 | forbes.com

Gossamer Bio

October 20, 2022 | cnbc.com

Goldman says buy this under-the-radar biopharma stock expected to rally nearly 80%

October 20, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Gossamer Bio

October 18, 2022 | finance.yahoo.com

Gossamer Bio, Inc. (GOSS)

October 17, 2022 | nasdaq.com

Gossamer Bio, Inc. (NASDAQ:GOSS) is favoured by institutional owners who hold 62% of the company

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Company Calendar

Last Earnings: 11/08/2021
Today: 2/05/2023
Next Earnings (Estimated): 3/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GOSS
CUSIP: N/A
CIK: 1728117
Web: www.gossamerbio.com
Phone: (858) 684-1300
Fax: N/A
Employees: 185
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.25
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +268.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-234,000,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -480.17%
Return on Assets: -76.14%

Debt

Debt-to-Equity Ratio: 3.73
Current Ratio: 5.93
Quick Ratio: 5.93

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.59 per share
Price / Book: 1.75

Miscellaneous

Outstanding Shares: 94,480,000
Free Float: 86,635,000
Market Cap: $262.65 million
Optionable: Not Optionable
Beta: 1.18

Key Executives

Faheem Hasnain
Chairman, President & Chief Executive Officer

Bryan Giraudo
Chief Operating & Financial Officer

Richard Aranda
Chief Medical Officer

Laura Carter
Chief Scientific Officer

Christian Waage
Secretary, General Counsel & Executive VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GOSS Stock - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GOSS shares.
View GOSS analyst ratings or view top-rated stocks.
What is Gossamer Bio's stock price forecast for 2023?: 10 brokerages have issued 1 year price targets for Gossamer Bio's stock. Their GOSS share price forecasts range from $2.00 to $24.00. On average, they predict the company's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 268.7% from the stock's current price.
View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts.
How have GOSS shares performed in 2023?: Gossamer Bio's stock was trading at $2.17 on January 1st, 2023. Since then, GOSS shares have increased by 28.1% and is now trading at $2.78.
View the best growth stocks for 2023 here.
When is Gossamer Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GOSS earnings forecast.
How were Gossamer Bio's earnings last quarter?: Gossamer Bio, Inc. (NASDAQ:GOSS) posted its earnings results on Monday, November, 8th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.02. During the same quarter in the previous year, the company earned ($0.80) EPS.
What other stocks do shareholders of Gossamer Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA).

When did Gossamer Bio IPO?: (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO.
What is Gossamer Bio's stock symbol?: Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."
Who are Gossamer Bio's major shareholders?: Gossamer Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Birchview Capital LP (0.10%), Simplex Trading LLC (0.00%), New York State Common Retirement Fund (0.05%), Sequoia Financial Advisors LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends.
How do I buy shares of Gossamer Bio?: Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Gossamer Bio's stock price today?: One share of GOSS stock can currently be purchased for approximately $2.78.
How much money does Gossamer Bio make?: Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $262.65 million. The company earns $-234,000,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.
How many employees does Gossamer Bio have?: The company employs 185 workers across the globe.
How can I contact Gossamer Bio?: Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.

This page (NASDAQ:GOSS) was last updated on 2/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gossamer Bio - GOSS Stock Forecast, Price & News

Gossamer Bio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Gossamer Bio (NASDAQ:GOSS) Stock

GOSS Stock News Headlines

GOSS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GOSS Stock - Frequently Asked Questions

Overall MarketRank^™